 EVANSTON, Ill.--BUSINESS WIRE--Aptinyx Inc. Nasdaq: APTX, a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has entered into a 50 million loan facility and security agreement with K2 HealthVentures K2HV. The funds will provide general growth capital as Aptinyx advances its late-stage clinical pipeline of novel NMDA modulators. Access to this capital provides us with additional f 